Golimumab for Adherence in Rheumatoid Arthritis (GO FAR)

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Arthritis, Rheumatoid

Treatments: Biological: Golimumab

Study type: Observational

Funder types: Industry

Identifiers

NCT03729349

CNTO148ARA4010 (Other Identifier)

CR108555

Details and patient eligibility

About

The purpose of this study is to determine if non-adherence to Rheumatoid Arthritis (RA) drugs in participants treated with biologic disease modifying anti-rheumatic drugs (DMARDs) is associated with a greater incidence of disease in clinical practice.

Enrollment: 222 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have a confirmed diagnosis of rheumatoid arthritis
• About to initiate therapy with golimumab
• Must sign a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements

Exclusion criteria

• Diagnosis of Axial Spondyloarthritis, Ankylosing Spondylitis or Psoriatic Arthritis
• Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the start of the study or the first data collection time point
• Currently enrolled in an investigational study
• Currently enrolled in an observational study sponsored or managed by a Janssen company

Trial design

222 participants in 1 patient group

Participants with Diagnosis of Rheumatoid Arthritis

Description:

Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.

Treatment:

Biological: Golimumab